Cyntellect has appointed Tina Nova to its board of directors, the San Diego-based company said last week.
Nova is currently the president, CEO, and co-founder of San Diego-based biotechnology firm Genoptix. She also co-founded Nanogen, where she served as chief operating officer and president from 1994 to 2000, and Selective Genetics, where she served as chief operating officer from 1992 to 1994. She has also held director-level positions with Ligand Pharmaceuticals.
Nova received a PhD in biochemistry from the University of California, Riverside, and conducted her postdoctoral research at New York University Medical School.
Illumina has named William Rastetter chairman of the board. Rastetter will continue full-time as the executive chairman of Biogen Idec. Before the 2003 merger between Idec Pharmaceuticals and Biogen, he was chairman and CEO of Idec, where he had served since 1986. Rastetter has also been employed by Genentech, and was an associate professor of chemistry at the Massachusetts Institute of Technology. He has been an Illumina board member since 1998.
Illumina also said that John Stuelpnagel has been promoted to the newly created position of chief operating officer. Stuelpnagel is one of Illumina’s founders, Jay Flatley, Illumina’s president and CEO, noted in a statement.